Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study found that oral finasteride, at a dosage of 2.5 mg/day or more, may improve hair growth and appearance in postmenopausal women with pattern hair loss, without adverse effects.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This study found that PRO 160/120 and Finasteride showed similar effectiveness in improving urinary symptoms and quality of life in patients with benign prostatic hyperplasia over 48 weeks.

This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This study found that long-term finasteride treatment in men with androgenetic alopecia significantly increased hair weight and count compared to placebo over nearly four years.

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This study suggests that finasteride may reduce the aggressiveness and invasion of prostate tumors, with effects potentially differing based on the androgen responsiveness of the patient's prostate cells.

This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.

This case series reported that three pediatric patients with hidradenitis suppurativa showed decreased frequency and severity of disease flares after treatment with oral finasteride, with no significant adverse effects.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

This study reported new crystallographic structures and polymorphs of finasteride, including several solvates with distinct X-ray diffraction patterns and thermally characterized properties.

The researchers reported that during early embryogenesis and larval development in Silurana tropicalis, inhibiting steroidogenic enzymes cyp19 and srd5beta affects genes related to thyroid and reproductive systems.

Both drugs lower DHT levels, with GI198745 being more effective.

This study suggests that finasteride may be a promising treatment for chronic central serous chorioretinopathy, but larger controlled trials are needed to confirm its efficacy.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.